Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: The HGCSG0801 study

Japanese Journal of Clinical Oncology

Volumn 41, Issue 4, 2011, Pages 490-497

  Sogabe, Susumu ^a   Komatsu, Yoshito ^a,b   Yuki, Satoshi ^a   Kusumi, Takaya ^c   Hatanaka, Kazuteru ^d   Nakamura, Michio ^e   Kato, Takashi ^f   Miyagishima, Takuto ^g   Hosokawa, Ayumu ^h   Iwanaga, Ichiro ^a,i   Sakata, Yuh ^j   Asaka, Masahiro ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^c Keiyukai Sapporo Hospital   (Japan)

^d Hakodate Municipal Hospital   (Japan)

^e SAPPORO CITY GENERAL HOSPITAL   (Japan)

^f Hokkaido Gastroenterology Hospital   (Japan)

^g KUSHIRO ROSAI HOSPITAL   (Japan)

^h UNIVERSITY OF TOYAMA   (Japan)

ⁱ Kitami Red Cross Hospital   (Japan)

^j Misawa City Hospital   (Japan)

more..

Author keywords

Bevacizumab; Chemotherapy; Colorectal neoplasms; Retrospective studies; Safety

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; HEMATURIA; HUMAN; HYPERTENSION; LIVER METASTASIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RETROSPECTIVE STUDY; THROMBOSIS; WOUND DEHISCENCE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COHORT STUDIES; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; EPISTAXIS; FEMALE; FLUOROURACIL; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYPERTENSION; JAPAN; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; PROTEINURIA; RETROSPECTIVE STUDIES; TEGAFUR; THROMBOSIS; TREATMENT OUTCOME;

EID: 79953751240     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr008     Document Type: Article

References (22)

1. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9.
2. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-99.
3. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
4. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-9.
5. Hecht RJ, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A randomized phase iiib trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27:672-80.
6. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007;25:4779-86.
7. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009;14:862-70.
8. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009;20:1842-47.
9. Uetake H, Shirao K, Doi T, Hatake K. Report of post marketing surveillance of anti-VEGF antibody Avastin® (bevacizumab) with colorectal cancer patients. Jpn J Gastroenterol Surg 2009;42:7.
10. Cassidy J, Saltz L, Giantonio B, Kabbinavar FF, Hurwitz HI, Rohr UP. Effect of bevacizumab in older patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 2010;136:737-43.
11. Kubala E, Bartos J, Petruzelka LB. Safety and effectiveness of bevacizumab (bev) in combination with chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): results from a large Czech observational registry (CSTP). In: Poster Presented at: Gastrointestinal Cancers Symposium 2010, Orlando, FL, USA, 22-24 January 2010.
12. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:3697-705.
13. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008;26:3523-9.
14. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44.
15. Takashima A, Yamada Y, Yamazaki K, Endo S, Esaki Y, Miyake Y, et al. Multicenter research of bevacizumab with FOLFIRI or FOLFOX in the 2nd or further line with unresectable metastatic colorectal cancer patients: 1st report. In: Abstract Presented at: the Seventh Annual Meeting of Japanese Society of Medical Oncology, Nagoya, Japan, 20-21 May 2009.
16. Nishi Y, Suenaga M, Shinozaki E, Matuzaka S, Watanabe T, Nozaki A, et al. Safety and efficacy of bevacizumab (Bev) and FOLFIRI with unresectable metastatic colorectal cancer patients. In: Abstract Presented at: the Seventh Annual Meeting of Japanese Society of Medical Oncology, Nagoya, Japan, 20-21 May 2009.
17. Yildiz R, Buyukberber S, Uner A, Yamac D, Coskun U, Kaya AO, et al. Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens. Cancer Invest 2010;28:33-7.
18. Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow L, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 2006;24:3354-60.
19. Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol 2007;13:6231-35.
20. Kang BW, Kim TW, Lee JL, Ryu MH, Chang HM, Yu CS, et al. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis. Med Oncol 2009;26:32-7.
21. Lièvre A, Samalin E, Mitry E, Assenat E, Boyer-Gestin C, Lepère C, et al. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapyrefractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer 2009;9:347.
22. Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 2010;11:853-60.